Aducanumab: A Deep Dive into BIIB037 and its Impact The medication, initially known as BIIB037, is a complex effort to address emerging Alzheimer's illness. Developed by Biogen, aducanumab functions by clearing amyloid https://www.targetmol.com/compound/aducanumab